Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis

Rheumatology (United Kingdom)

Volumn 53, Issue 4, 2014, Pages 686-695

  Guo, Xiang ^a   Higgs, Brandon W ^a   Rebelatto, Marlon ^a   Zhu, Wei ^a   Greth, Warren ^a   Yao, Yihong ^a   Roskos, Lorin K ^a   White, Wendy I ^a  

^a MEDIMMUNE   (United States)

Author keywords

Dermatomyositis; Polymyositis; Soluble interleukin 2 receptor; T cell infiltration; Type I interferon

Indexed keywords

ALPHA1 INTERFERON; ANGIOPOIETIN 2; B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; CD3 ANTIBODY; FERRITIN; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; SIFALIMUMAB; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LIMIT OF QUANTITATION; LYMPHOCYTIC INFILTRATION; MALE; MANUAL MUSCLE TEST 8; MIDDLE AGED; MULTICENTER STUDY; MUSCLE BIOPSY; MUSCLE LEVEL; PHASE 1 CLINICAL TRIAL; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION; UPREGULATION;

DERMATOMYOSITIS; POLYMYOSITIS; SOLUBLE INTERLEUKIN-2 RECEPTOR; T CELL INFILTRATION; TYPE I INTERFERON;

ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL; DERMATOMYOSITIS; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-18; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; MUSCLE, SKELETAL; POLYMYOSITIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84897833614     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket413     Document Type: Article

References (41)

1. Dalakas MC. Review: an update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011;37:226-42.
2. Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther 2010;12(Suppl 1):S4.
3. Greenberg SA, Higgs BW, Morehouse C et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2011;13:207-13.
4. Bilgic H, Ytterberg SR, Amin S et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60:3436-46.
5. Hengstman GJ, Vogels OJ, ter Laak HJ et al. Myositis during long-term interferon-alpha treatment. Neurology 2000;54:2186.
6. Greenberg SA, Pinkus JL, Pinkus GS et al. Interferonalpha/ beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78.
7. Isenberg DA, Rowe D, Shearer M et al. Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 1986;63:450-8.
8. Higgs BW, Zhu W, Morehouse C et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2013.
9. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
10. Salajegheh M, Kong SW, Pinkus JL et al. Interferonstimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010;67:53-63.
11. Wenzel J, Schmidt R, Proelss J et al. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 2006;31:576-82.
12. Benjamini Y, Drai D, Elmer G et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-84.
13. Yao Y, Higgs BW, Morehouse C et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009;2009:374312.
14. Samarajiwa SA, Forster S, Auchettl K et al. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res 2009;37:D852-7.
15. Baek A, Park HJ, Na SJ et al. The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 2012;249:96-100.
16. De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009;21:610-6.
17. Kobayashi I, Ono S, Kawamura N et al. Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis. Pediatr Int 2001;43:109-11.
18. Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E et al. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int 2012;32:639-43.
19. Jain A, Sharma MC, Sarkar C et al. Increased expression of cell adhesion molecules in inflammatory myopathies: diagnostic utility and pathogenetic insights. Folia Neuropathol 2009;47:33-42.
20. Hermansen ML, Hummelshoj L, Lundsgaard D et al. Increased serum beta2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients. Lupus 2012;21:1098-104.
21. Michalska-Jakubus M, Kowal-Bielecka O, Chodorowska G et al. Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology 2011;50:746-55.
22. Kumpers P, David S, Haubitz M et al. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann Rheum Dis 2009;68:163843.
23. Chen X, Hamano R, Subleski JJ et al. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. J Immunol 2010;185:174-82.
24. Caruso C, Candore G, Cigna D et al. Biological significance of soluble IL-2 receptor. Mediators Inflamm 1993;2:3-21.
25. Kim EY, Teh HS. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol 2004;173:4500-9.
26. Mackay F, Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006;18:284-9.
27. Weninger W, Carlsen HS, Goodarzi M et al. Naive T cell recruitment to nonlymphoid tissues: a role for endothelium- expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. J Immunol 2003;170:4638-48.
28. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
29. Jurewicz AM, Walczak AK, Selmaj KW. Shedding of TNF receptors in multiple sclerosis patients. Neurology 1999;53:1409-14.
30. Tokano Y, Kanai Y, Hashimoto H et al. Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis. Ann Rheum Dis 1992;51:781-2.
31. Tucci M, Quatraro C, Dammacco F et al. Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 2006;146:21-31.
32. Gabay C, Gay-Croisier F, Roux-Lombard P et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/ dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994;37:1744-51.
33. Matikainen S, Sareneva T, Ronni T et al. Interferonalpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999;93:1980-91.
34. Wenner CA, Guler ML, Macatonia SE et al. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 1996;156:1442-7.
35. Sugimura T, Motomura S, Sakai H et al. Increased serum soluble IL-2 receptor levels following interferon therapy in patients with chronic hepatitis C. Hepatogastroenterology 1999;46:1827-30.
36. Liprandi A, Bartoli C, Figarella-Branger D et al. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol 1999;97:642-8.
37. De Paepe B, De Bleecker JL. Beta-chemokine receptor expression in idiopathic inflammatory myopathies. Muscle Nerve 2005;31:621-7.
38. Mannucci PM. von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998;18:1359-62.
39. Cook-Mills JM, Deem TL. Active participation of endothelial cells in inflammation. J Leukoc Biol 2005;77:487-95.
40. Scholz A, Lang V, Henschler R, Czabanka M et al. Angiopoietin-2 promotes myeloid cell infiltration in a beta-integrin-dependent manner. Blood 2011;118:5050-9.
41. Bloom BJ, Tucker LB, Miller LC et al. von Willebrand factor in juvenile dermatomyositis. J Rheumatol 1995;22:320-5.